NEURAPRO: A multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders - Medium-term follow-up and clinical course

npj Schizophrenia

Volumn 4, Issue 1, 2018, Pages

  Nelson, B ^a,b   Amminger, G P ^a,b,c   Yuen, H P ^a,b   Markulev, C ^a,b   Lavoie, S ^a,b   Schafer M R ^a,c   Hartmann, J A ^a,b   Mossaheb, N ^c   Schlogelhofer M ^c   Smesny, S ^d   Hickie, I B ^e   Berger, G ^f   Chen, E Y H ^g   De Haan, L ^h   Nieman, D H ^h   Nordentoft, M ⁱ   Riecher Rossler A ^j   Verma, S ^k   Thompson, A ^a,l,m   Yung, A R ^a,n,o   McGorry, P D ^a,b   more..

^a THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Child and Adolescent Psychiatric Service   (Switzerland)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ Psychiatric Centre Bispebjerg   (Denmark)

^j UNIVERSITY OF BASEL   (Switzerland)

^k INSTITUTE OF MENTAL HEALTH   (Singapore)

^l UNIVERSITY OF WARWICK   (United Kingdom)

^m University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; PLACEBO;

ADULT; ARTICLE; ASIA; AUSTRALIA; CASE MANAGEMENT; CLINICAL OUTCOME; COGNITIVE BEHAVIOURAL CASE MANAGEMENT; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MENTAL HEALTH SERVICE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 85052688321     PISSN: None     EISSN: 2334265X     Source Type: Journal    
DOI: 10.1038/s41537-018-0052-x     Document Type: Article

References (60)

1. Yung, A. R. et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 22, 283-303 (1996).
2. Yung, A. R. & McGorry, P. D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 22, 353-370 (1996).
3. Yung, A. R. et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 60, 21-32 (2003).
4. Fusar-Poli, P. et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70, 107-120 (2013).
5. van der Gaag, M. et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr. Res. 149, 56-62 (2013).
6. Stafford, M. R., Jackson, H., Mayo-Wilson, E., Morrison, A. P. & Kendall, T. Early interventions to prevent psychosis: systematic review and meta-analysis. Br. Med. J. 346, f185 (2013).
7. Hutton, P. & Taylor, P. J. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol. Med. 44, 1-20 (2013).
8. McGorry, P. & Nelson, B. Why we need a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment. JAMA Psychiatry 73, 1-2 (2016).
9. McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C. & Jackson, H. J. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust. N. Z. J. Psychiatry 40, 616-622 (2006).
10. McGorry, P. D. Risk syndromes, clinical staging and DSM V: new diagnostic infrastructure for early intervention in psychiatry. Schizophr. Res. 120, 49-53 (2010).
11. McGorry, P. D. The next stage for diagnosis: validity through utility. World Psychiatry 12, 213-215 (2013).
12. McGorry, P. D. Early clinical phenotypes, clinical staging, and strategic biomarker research: building blocks for personalized psychiatry. Biol. Psychiatry 74, 394-395 (2013).
13. Addington, J. et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr. Res. 125, 54-61 (2011).
14. Morrison, A. P. et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 185, 291-297 (2004).
15. Morrison, A. P. et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr. Bull. 33, 682-687 (2007).
16. Morrison, A. P. et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. Br. Med. J. 344, e2233 (2012).
17. van der Gaag, M. et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr. Bull. 38, 1180-1188 (2012).
18. Ising, H. K. et al. Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch early detection intervention evaluation (EDIE-NL) trial. Schizophr. Bull. 42, 1243-1252 (2016).
19. Stain, H. J. et al. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophr. Res. 176, 212-219 (2016).
20. Amminger, G. P. et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67, 146-154 (2010).
21. Amminger, G. P., Schafer, M. R., Schlogelhofer, M., Klier, C. M. & McGorry, P. D. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat. Commun. 6, 7934 (2015).
22. McGorry, P. D. et al. Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry 74, 19-27 (2017).
23. Markulev, C. et al. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Interv. Psychiatry 11, 418-428 (2015).
24. Phillips, L. J. et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr. Res. 96, 25-33 (2007).
25. McGlashan, T. H. et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 163, 790-799 (2006).
26. McGlashan, T. H. et al. Olanzapine for treatment of the schizophrenia prodrome: 2 year results of a randomized placebo-controlled study. World J. Biol. Psychiatry 5, 146 (2004).
27. Bechdolf, A. et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br. J. Psychiatry 200, 22-29 (2012).
28. Nelson, B. et al. Staged treatment in early psychosis: a sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Early Interv. Psychiatry. https://doi.org/10.1111/eip.12459 (2017).
29. Fusar-Poli, P., Valmaggia, L. & McGuire, P. Can antidepressants prevent psychosis? Lancet 370, 1746-1748 (2007).
30. Cantor-Graae, E. The contribution of social factors to the development of schizophrenia: a review of recent findings. Can. J. Psychiatry 52, 277-286 (2007).
31. Chen, G. et al. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom. Med. 61, 599-617 (1999).
32. Michael-Titus, A. T., Bains, S., Jeetle, J. & Whelpton, R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 100, 681-684 (2000).
33. Sanchez, V. et al. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol. 134, 46-57 (2001).
34. Nelson, B. et al. Further examination of the reducing transition rate in ultra high risk for psychosis samples: the possible role of earlier intervention. Schizophr. Res. 174, 43-49 (2016).
35. Fusar-Poli, P. et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry 73, 1260-1267 (2016).
36. Fusar-Poli, P. et al. Why transition risk to psychosis is not declining at the OASIS ultra high risk service: the hidden role of stable pretest risk enrichment. Schizophr. Res. 192, 385-390 (2017).
37. Wiltink, S., Velthorst, E., Nelson, B., McGorry, P. M. & Yung, A. R. Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv. Psychiatry 9, 200-206 (2015).
38. Hartmann, J. A. et al. Declining transition rates to psychotic disorder in "ultra-high risk" clients: investigation of a dilution effect. Schizophr. Res. 170, 130-136 (2016).
39. Nelson, B. et al. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. JAMA Psychiatry 70, 793-802 (2013).
40. Cannon, T. D. et al. An individualized risk calculator for research in prodromal psychosis. Am. J. Psychiatry 173, 980-988 (2016).
41. Mason, O. et al. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. Schizophr. Res. 71, 227-237 (2004).
42. Yung, A. R. et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 39, 964-971 (2005).
43. Haroun, N., Dunn, L., Haroun, A. & Cadenhead, K. S. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 32, 166-178 (2006).
44. Bijl, R. V. & Ravelli, A. Current and residual functional disability associated with psychopathology: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol. Med. 30, 657-668 (2000).
45. Joffe, H. et al. Lifetime history of depression and anxiety disorders as a predictor of quality of life in midlife women in the absence of current illness episodes. Arch. Gen. Psychiatry 69, 484-492 (2012).
46. Group, T. P. M. W. The PACE Clinic Manual: A Treatment Approach for Young People at Ultra High Risk of Psychosis (Orygen Youth Health, Melbourne, 2012).
47. Yuen, H. P., Mackinnon, A. & Nelson, B. A method for analysing transition to psychosis: joint modelling of time-to-event outcome with time-dependent predictors. Int. J. Methods Psychiatr. Res. https://doi.org/10.1002/mpr.1588 (2017).
48. Nelson, B., McGorry, P. D., Wichers, M., Wigman, J. T. W. & Hartmann, J. Moving from static to dynamic models of the onset of mental disorder. JAMA Psychiatry 74, 528-534 (2017).
49. Lin, A. et al. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am. J. Psychiatry 172, 249-258 (2015).
50. Woods, S. W. E. A. Lack of diagnostic pluripotentiality in patients at clinical high risk for psychosis: speci city of comorbidity persistence and search for pluripotential subgroups. Schizophr. Bull. https://doi.org/10.1093/schbul/sbx138 (2017).
51. Allott, K., Chanen, A. & Yuen, H. P. Attrition bias in longitudinal research involving adolescent psychiatric outpatients. J. Nerv. Ment. Dis. 194, 958-961 (2006).
52. Hartmann, J. A. et al. Opening the black box of cognitive-behavioural case management in clients with ultra-high risk for psychosis. Psychother. Psychosom. 86, 292-299 (2017).
53. World Medical, A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J. Am. Med. Assoc. 310, 2191-2194 (2013).
54. Overall, J. E. & Gorham, D. R. The brief psychiatric rating scale. Psychol. Rep. 10, 799-812 (1962).
55. Andreasen, N. C. Scale for the Assessment of Negative Symptoms (SANS) (University of Iowa, Iowa City, 1983).
56. Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979).
57. Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133, 429-435 (1978).
58. Goldman, H. H., Skodol, A. E. & Lave, T. R. Revising axis V for DSM-IV: a review of measures of social functioning. Am. J. Psychiatry 149, 1148-1156 (1992).
59. Auther, A., Smith, C. & Cornblatt, B. Global Functioning: Social Scale (GF: Social) (Zucker-Hillside Hospital, New York, 2006).
60. Niendam, T. A., Bearden, C. E., Johnson, J. K. & TD, C. Global Functioning: Role Scale (GF: Role). (University of California, Los Angeles, 2006).